Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-05-11
1997-08-05
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4242041, 530350, 530395, A61K 3921, A61K 3912, C07K 100, C07K 1400
Patent
active
056539851
ABSTRACT:
A method for purifying recombinant HIV gp120 so as to provide a glycopeptide having protein/protein binding properties substantially identical to natural viral HIV gp120, which comprises fractionating a composition containing crude gp120 sequentially using (1) ion exchange chromatography, (2) hydrophobic-interaction chromatography, and (3) size exclusion filtration, collecting at each step a fraction that exhibits specific binding affinity for CD4 peptide. The process is carried out in the absence of any affinity purification steps or any steps (such as reverse-phase HPLC) that use contact protein with organic solvents. The product obtained by this method is a purified, full-length, non-fusion recombinant HIV gp120 glycoprotein having protein/protein-interaction properties substantially identical to gp120 as presented on an HIV virus, including binding affinity for CD4 and binding affinity for at least one antibody capable of neutralizing HIV infectivity.
REFERENCES:
Arthur et al., "Serological Responses in Chimpanzees inoculated with Human Immunodeficiency Virus Glycoprotein (gp120) Subunit Vaccine," Proc. Natl. Acad. Sci. USA 84:8583-8587 (Dec. 1987).
Barrett et al., "Large-Scale Production and Purification of a Vaccinia Recombinant-Derived HIV-1 gp160 and Analysis of its Immunogenicity," Aids Research and Human Retrovirus, vol. 5, No. 2 (1989).
Berman et al., "Human Immunodeficiency Virus Type 1 Challenge of Chimpanzees Immunized with Recombinant Envelope Glycoprotein gp120," Proc. Natl. Acad. Sci. USA 95:5200-5204 (Jul. 1988).
Berman et al., "Expression and Immunogenicity of the Extracellular Domain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, gp160," J. Virol. pp. 3489-3498 (Aug. 1989).
Brown, "AIDS Vaccine Trials Viewed with Caution," The Washington Post Newspaper, Jun. 10, 1993.
Bulognesi, "Progress in Vaccine Against Aids," Science, 246:1233-1234 (1989).
Cohen, "Jitters Jeopardize AIDS Vaccine . . . ," Science 262:980-981.
Earl et al., "Isolate-and Group-Specific Immune Responses to the Envelope Protein of Human Immunodeficiency Virus Induced by a Live Recombinant Vaccinia Virus in Macaques," Aids Research and Human Retroviruses, vol. 5, No. 1 (1989).
Edelman, Reviews of Infectious Diseases vol. 2, No. 3 (May-Jun. 1980).
Evans et al., "An Engineered Poliovirus Chimaera Elicits Broadly Reactive HIV-1 Neutralizing Antibodies," Nature 339:385-388 (Jun. 1989).
Fennie et al., "Model for Intracellular Folding of the Human Immunodeficiency Virus Type 1 gp120," J. Virol. pp. 639-646 (Feb. 1989).
Greene, "AIDS and the Immune System," Scientific American pp. 99-105 (Sep. 1993).
Haynes, "Scientific and Social Issues of . . . ," Science 260:1279-1286.
Ho et al., "Human Immunodeficiency Virus Neutralizing Antibodies Recognize Several Conserved Domains on the Envelope Glycoproteins," J. Virol. pp. 2024-2028 (Jun. 1987).
Kreuter et al., Infection and Immunity pp. 667-675 (Feb. 1978).
Lasky et al., "Delineation of a Region of the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein Critical for Interaction with the CD4 Receptor," Cell 50:975-985 (1987).
Littman et al., Nature 325:453-455 (Jan. 1987).
Maddon et al., "The Isolation and Nucleotide Sequence of a cDNA Encoding the T Cell Surface Protein T4: a New Member of the Immunoglobulin Gene Family," Cell 42:93-104 (Aug. 1985).
Modrow et al., J. Virol., pp. 570-578 (Feb. 1987).
Nara et al., "Purified Envelope Glycoproteins from Human Immunodeficiency Virus Type 1 Variants Induced Individual, Type-Specific Neutralizing Antibodies," J. Virol. pp. 2622-2628 (Aug. 1988).
Palker et al., "Type-Specific Neutralization of the Human Immunodeficiency Virus with Antibodies to Env-Encoded Synthetic Peptides," Proc. Natl. Acad. Sci. USA 85:1932-1936 (Mar. 1988).
Putney et al., "HTLV-III/LAV-Neutralizing Antibodies to an E. coli-Produced Fragment of the Virus Envelope," Science 234:1392-1395 (1986).
Pyle et al., "Immune Response to Immunostimulatory Complexes (ISCOMs) Prepared from Human Immunodeficiency Virus Type 1 (HIV-1) or the HIV-1 External Envelope Glycoprotein (gp120)," Vaccine 7:465-473 (1989).
Robey et al., "Prospect for Prevention of Human Immunodeficiency . . . ", Proc. Natl. Acad. Sci. USA 83:7023-7027 (1986).
Scandella et al., "Purification of HIV-1 gp120 Retaining Receptor Binding Activity" Abstract Draft, First Conference on Advances in Purification of Recombinant Proteins, Interlaken, Switzerland, Mar. 14-17, 1989.
Smith et al., "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen," Science 228:1704-1707.
Steimer et al., "Genetically Engineered Human Immunodeficiency Envelope Glycoprotein gp120 Produced in Yeast is the Target of Neutralizing Antibodies," Vaccines 87:236-241 (1987).
Steimer et al., "Recombinant Env and Gag Polypeptides in Characterizing HIV-1-Neutralizing Antibodies," Vaccines 88:347-354 (1988).
Strinivasan et al., Gene 52:71-82 (1987).
Haigwood Nancy L.
Scandella Carl
Blackburn Robert P.
Chiron Corporation
Harbin Alisa A.
McCracken Thomas P.
Smith Lynette F.
LandOfFree
Purified gp120 composition retaining natural conformation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified gp120 composition retaining natural conformation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified gp120 composition retaining natural conformation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1072957